1. McKeith, IG, Galasko, D, Kosaka, K, et al Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–1124.
Google Scholar2. Barker, WW, Luis, CA, Kashuba, A, et al Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002; 16: 203–212.
Google Scholar | Crossref | Medline | ISI3. Goodman, RA, Lochner, KA, Thambisetty, M, et al Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement 2017; 13: 28–37.
Google Scholar | Crossref | Medline4. Hansen, L, Salmon, D, Galasko, D, et al The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 1990; 40: 1–8.
Google Scholar | Crossref | Medline | ISI5. Savica, R, Beach, TG, Hentz, JG, et al Lewy body pathology in Alzheimer’s disease: a clinicopathological prospective study. Acta Neurol Scand 2019; 139: 76–81.
Google Scholar | Crossref | Medline6. McKeith, IG, Boeve, BF, Dickson, DW, et al Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88–100.
Google Scholar | Crossref | Medline7. Hughes, AJ, Daniel, SE, Kilford, L, et al Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
Google Scholar | Crossref | Medline | ISI8. Berg, D, Postuma, RB, Bloem, B, et al Time to refine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 2014; 29: 454–462.
Google Scholar | Crossref | Medline9. Postuma, RB, Berg, D, Stern, M, et al MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591–1601.
Google Scholar | Crossref | Medline | ISI10. Postuma, RB, Berg, D, Stern, M, et al Abolishing the 1-year rule: how much evidence will be enough. Mov Disord 2016; 31: 1623–1627.
Google Scholar | Crossref | Medline11. Boeve, BF, Dickson, DW, Duda, JE, et al Arguing against the proposed definition changes of PD. Mov Disord 2016; 31: 1619–1622.
Google Scholar | Crossref | Medline12. Thomas, AJ, Taylor, JP, McKeith, I, et al Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. Int J Geriatr Psychiatry 2017; 32: 1280–1304.
Google Scholar | Crossref | Medline13. Galvin, JE, Duda, JE, Kaufer, DI, et al Lewy body dementia: the caregiver experience of clinical care. Parkinsonism Relat Disord 2010; 16: 388–392.
Google Scholar | Crossref | Medline14. Ngo, J, Holroyd-Leduc, JM. Systematic review of recent dementia practice guidelines. Age Ageing 2015; 44: 25–33.
Google Scholar | Crossref | Medline | ISI15. Armstrong, MJ, Irwin, DJ, Leverenz, JB, et al Biomarker use for dementia with Lewy body diagnosis: survey of US experts. Alzheimer Dis Assoc Disord 2021; 35: 55–61.
Google Scholar | Crossref | Medline16. Attems, J, Toledo, JB, Walker, L, et al Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol 2021; 141: 159–172.
Google Scholar | Crossref | Medline17. Irwin, DJ, Hurtig, HI. The contribution of tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders. J Alzheimers Dis Parkinsonism 2018; 8: 444.
Google Scholar | Crossref | Medline18. Ferman, TJ, Aoki, N, Boeve, BF, et al Subtypes of dementia with Lewy bodies are associated with alpha-synuclein and tau distribution. Neurology 2020; 95: e155–e165.
Google Scholar | Crossref | Medline19. Ferman, TJ, Aoki, N, Crook, JE, et al The limbic and neocortical contribution of alpha-synuclein, tau, and amyloid beta to disease duration in dementia with Lewy bodies. Alzheimers Dement 2018; 14: 330–339.
Google Scholar | Crossref | Medline20. de Oliveira, FF, Miraldo, MC, de Castro-Neto, EF, et al Associations of neuropsychiatric features with cerebrospinal fluid biomarkers of amyloidogenesis and neurodegeneration in dementia with Lewy bodies compared with Alzheimer’s disease and cognitively healthy people. J Alzheimers Dis 2021; 81: 1295–1309.
Google Scholar | Crossref | Medline21. Galbiati, A, Verga, L, Giora, E, et al The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med Rev 2019; 43: 37–46.
Google Scholar | Crossref | Medline22. Savica, R, Boeve, BF, Mielke, MM. When do alpha-synucleinopathies start? An epidemiological timeline: a review. JAMA Neurol 2018; 75: 503–509.
Google Scholar | Crossref | Medline23. Ferman, TJ, Smith, GE, Kantarci, K, et al Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 2013; 81: 2032–2038.
Google Scholar | Crossref | Medline | ISI24. Sadiq, D, Whitfield, T, Lee, L, et al Prodromal dementia with Lewy bodies and prodromal Alzheimer’s disease: a comparison of the cognitive and clinical profiles. J Alzheimers Dis 2017; 58: 463–470.
Google Scholar | Crossref | Medline25. Cagnin, A, Bussè, C, Gardini, S, et al Clinical and cognitive phenotype of mild cognitive impairment evolving to dementia with Lewy bodies. Dement Geriatr Cogn Dis Extra 2015; 5: 442–449.
Google Scholar | Crossref | Medline26. McKeith, IG, Ferman, TJ, Thomas, AJ, et al Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020; 94: 743–755.
Google Scholar | Crossref | Medline27. Biomarkers Definitions Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.
Google Scholar | Crossref | Medline | ISI28. Schneider, J, Jeon, S, Gladman, JT, et al ADRD summit 2019 report to the National Advisory Neurological Disorders and Stroke Council. In: Alzheimer’s disease-related dementias summit, 14–15 March 2019. Bethesda, MD: National Institutes of Health, https://www.ninds.nih.gov/sites/default/files/2019_adrd_summit_recommendations_508c.pdf (accessed 13 September 2021).
Google Scholar29. Armstrong, MJ, Gamez, N, Alliance, S, et al Research priorities of caregivers and individuals with dementia with Lewy bodies: an interview study. PLoS ONE 2020; 15: e0239279.
Google Scholar | Crossref | Medline30. Scamarcia, PG, Agosta, F, Caso, F, et al Update on neuroimaging in non-Alzheimer’s disease dementia: a focus on the Lewy body disease spectrum. Curr Opin Neurol 2021; 34: 532–538.
Google Scholar | Crossref | Medline31. Thomas, AJ, Attems, J, Colloby, SJ, et al Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 2017; 88: 276–283.
Google Scholar | Crossref | Medline32. Kantarci, K, Lowe, VJ, Chen, Q, et al Beta-amyloid PET and neuropathology in dementia with Lewy bodies. Neurology 2020; 94: e282–e291.
Google Scholar | Crossref | Medline33. Ferreira, D, Przybelski, SA, Lesnick, TG, et al Beta-amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology 2020; 95: e3257–e3268.
Google Scholar | Crossref | Medline34. Irwin, DJ, Xie, SX, Coughlin, D, et al CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology 2018; 90: e1038–e1046.
Google Scholar | Crossref | Medline35. Abdelnour, C, van Steenoven, I, Londos, E, et al Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov Disord 2016; 31: 1203–1208.
Google Scholar | Crossref | Medline36. Bongianni, M, Ladogana, A, Capaldi, S, et al Alpha-synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol 2019; 6: 2120–2126.
Google Scholar | Crossref | Medline37. Bargar, C, Wang, W, Gunzler, SA, et al Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 2021; 9: 62.
Google Scholar | Crossref | Medline38. Rossi, M, Baiardi, S, Teunissen, CE, et al Diagnostic value of the CSF alpha-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 2021; 9: e930–e940.
Google Scholar | Crossref39. Laske, C, Fallgatter, AJ, Stransky, E, et al Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer’s disease patients and control subjects. Dement Geriatr Cogn Disord 2011; 31: 413–416.
Google Scholar | Crossref | Medline40. Senanarong, V, Wachirutmangur, L, Rattanabunnakit, C, et al Plasma alpha synuclein (a-syn) as a potential biomarker of diseases with synucleinopathy. Alzheimers Dement 2020; 16: e044409.
Google Scholar | Crossref41. Donadio, V, Incensi, A, Rizzo, G, et al A new potential biomarker for dementia with Lewy bodies: skin nerve alpha-synuclein deposits. Neurology 2017; 89: 318–326.
Google Scholar | Crossref | Medline42. Manne, S, Kondru, N, Jin, H, et al Blinded RT-QuIC analysis of alpha-synuclein biomarker in skin tissue from Parkinson’s disease patients. Mov Disord 2020; 35: 2230–2239.
Google Scholar | Crossref | Medline43. Wang, Z, Becker, K, Donadio, V, et al Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 2021; 78: 30–40.
Google Scholar | Crossref44. Al-Qassabi, A, Tsao, TS, Racolta, A, et al Immunohistochemical detection of synuclein pathology in skin in idiopathic rapid eye movement sleep behavior disorder and parkinsonism. Mov Disord 2021; 36: 895–904.
Google Scholar | Crossref | Medline45. Mammana, A, Baiardi, S, Quadalti, C, et al RT-QuIC detection of pathological alpha-synuclein in skin punches of patients with Lewy body disease. Mov Disord 2021; 36: 2173–2177.
Google Scholar | Crossref | Medline46. Donadio, V, Wang, Z, Incensi, A, et al In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology 2021; 96: e2513–e2524.
Google Scholar | Crossref | Medline47. Law, ZK, Todd, C, Mehraram, R, et al The role of EEG in the diagnosis, prognosis and clinical correlations of dementia with Lewy bodies – a systematic review. Diagnostics 2020; 10: 616.
Google Scholar | Crossref48. Mueller, C, Soysal, P, Rongve, A, et al Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: a meta-analysis of longitudinal studies. Ageing Res Rev 2019; 50: 72–80.
Google Scholar | Crossref | Medline49. Armstrong, MJ, Alliance, S, Corsentino, P, et al Cause of death and end-of-life experiences in dementia with Lewy bodies. J Am Geriatr Soc 2019; 67: 67–73.